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Background: Positron emission tomography (PET) imaging is routinely used in many cancer types, although is not
yet a standard modality for prostate carcinoma. Prostate-specific membrane antigen (PSMA) PET is a promising new
modality for staging prostate cancer, with recent studies showing potential advantages over traditional computed
tomography (CT), magnetic resonance imaging (MRI) and nuclear medicine bone scan imaging. However, the
impact of PSMA PET on the decision-making of radiation oncologists and outcomes after radiotherapy is yet to be
determined. Our aim was to determine the impact of PSMA PET on a radiation oncologist’s clinical practice.
Findings: Patients in a radiation oncology clinic who underwent PSMA PET were prospectively recorded in an
electronic oncology record. Patient demographics, outcomes of imaging, and impact on decision-making were
evaluated.
Fifty-four patients underwent PSMA PET between January and May 2015. The major reasons for undergoing PET
included staging before definitive (14.8 %) or post-prostatectomy (33.3 %) radiotherapy, and investigation of PSA
failures following definitive (16.7 %) or post-prostatectomy (33.3 %) radiotherapy. In 46.3 % of patients PSMA was
positive after negative traditional imaging, in 9.3 % PSMA was positive after equivocal imaging, and in 13.0 % PSMA
was negative after equivocal imaging. PSMA PET changed radiotherapy management in 46.3 % of cases, and
hormone therapy in 33.3 % of patients, with an overall change in decision-making in 53.7 % of patients.
Conclusions: PSMA PET has the potential to significantly alter the decision-making of radiation oncologists, and
may become a valuable imaging tool in the future.
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Findings
Introduction
Positron emission tomography (PET) imaging is a com-
mon staging tool in a variety of malignancies, with early
investigations demonstrating the potential utility of
prostate-specific membrane antigen (PSMA) for the de-
tection of prostate cancer [1, 2]. PSMA is a very spe-
cific prostate epithelial cell membrane antigen which is
significantly over-expressed in prostate cancer cells
compared to other PSMA-expressing tissues such as
kidney, proximal small intestine, and salivary glands
[3]. Unlike PSA, PSMA is membrane-bound and not
secreted [4]. These characteristics make it an ideal
extracellular target for imaging modalities [5].
Early studies have shown that PSMA PET has sensitivity,
specificity, negative predictive values (NPV) and positive
predictive values (PPV) of up to 76.6, 100, 91.4 and 100 %
respectively [1]. A critical review of the PET literature [2]
compared PSMA with four other tracers (11C- or 18F-cho-
line, 11C-acetate, anti-1-amino-3-18F-fluorocyclobutane-1-
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carboxylic acid, and 18F-fluorodeoxyglucose) in the detec-
tion of prostate cancer. This review demonstrated a poten-
tial advantage for the use of PSMA over other PET tracers
for prostate cancer, with PSMA having a greater likelihood
of detecting lymph node and bone lesions. However the
authors noted that at the time of the review in 2014, there
was fairly limited data on the use of PSMA.
Since the publication of Yu’s review, several studies
have demonstrated the potential benefits of PSMA PET
in identifying prostate cancer recurrences after surgery
[1, 6] and radiotherapy [1]. In these studies PSMA PET
was shown to convert PSA-only failures to metastatic
failures through the early detection of recurrences. The
ability of PSMA-PET to change the known outcome of
treated prostate cancer might conceivably have an im-
pact on the decision-making of clinicians, and poten-
tially change management approaches. There is one
published report of 22 patients evaluating the effect of
PSMA PET on the clinical decision-making of urologists
[5], showing it “significantly impacted” upon how pa-
tients were managed. However to date there has been no
evaluation of the potential effects of PSMA PET on
decision-making from a radiation oncology perspective.
The aim of this study was to evaluate how PSMA PET
changed the decision-making process and management
outcomes within a radiation oncology clinic.
Methods
Between January and May 2015, a total of 54 patients at-
tending a radiation oncology clinic were referred for
PSMA-PET imaging. Patients were only considered for
PET if conventional staging including CT, bone scan and/
or MRI was not definitive, if there was a high clinical sus-
picion despite negative or equivocal imaging, or if patients
were being considered for radiotherapy to oligometastatic
disease (defined as 1–3 nodal or distant metastases).
Intended management of patients was based on standard
departmental protocol. Patients with PSA-only failures
under 10 were planned for observation. Those with PSA
failures above 10, or PSA <10 with demonstrated systemic
metastases on imaging were planned for treatment with
androgen deprivation therapy (ADT). Patients with oligo-
metastatic disease were planned to have high dose radio-
therapy +/− systemic therapy.
All patients undergoing PSMA PET had tomographic
images obtained from the skull vertex to knees follow-
ing the intravenous injection of 159 MBq Ga-68 ligand
(Ga-68 PSMA). A low dose CT scan was performed
using tidal respiration for attenuation correction and
lesion localisation.
Patients sent for PSMA PET were prospectively tagged
within an electronic oncology record system. Patient files
were retrospectively evaluated for PET outcome and man-
agement received. This retrospective review completed
institutional ethics processes and was assigned the refer-
ence number QA101. Uni- and multivariate analyses were
performed using binary logistic regression for the variables
patient age, initial PSA, Gleason score and stage, and pre-
PET PSA.
Results
Patient demographics and reasons for PSMA PET are
shown in Table 1. Of note 26 (48.1 %) of patients were
being considered for curative doses of radiotherapy
(either in the definitive or post-prostatectomy setting),
and 27 (50.0 %) were to investigate PSA failures after de-
finitive or post-prostatectomy radiotherapy, with a view
to considering high dose radiotherapy if oligometastatic
disease was found.
The effect of PSMA PET on disease status outcomes
and decision-making are shown in Table 2. In 46.3 % of
patients PSMA was positive when conventional imaging
was negative. In 13.0 % of cases, equivocal conventional
imaging was negative on PSMA, and in 9.3 %, equivocal
conventional imaging was positive on PSMA.
In all, 53.7 % of patients had a change in management
due to the PSMA PET (Table 2), with 46.3 % having a
change in radiotherapeutic management, and 33.3 % a
change in ADT management. Treatment plans pre- and
post-PET are shown in Table 3. Of particular note, prior
to PET 50.0 % were planned for observation and this
reduced to 18.5 % after PET. In addition 9.3 % were
planned for treatment to oligometastases pre-PET and
this increased to 37.0 % post PET. Several of the patients
who were planned for oligometastatic treatment pre-
PET had the number and/or location of sites changed as
a result of PSMA PET.
Table 1 Patient demographics
Age (years) Median 69
Range 52–83
Gleason† 6–7 33 (61.1 %)
8–9 20 (37.0 %)
Initial PSA Median 9.15
Range 1.3–36.0
Pre-PSMA PSA Median 1.1
Range 0.017–20.4
Reason for PET n (%) Pre-radical IMRT staging 8 (14.8 %)
Pre-PPRT staging 18 (33.3 %)
PSA failure after IMRT 9 (16.7 %)
PSA failure after PPRT 18 (33.3 %)
Response to systemic therapy 1 (1.9 %)
†1 missing
IMRT = intensity-modulated radiotherapy
PPRT = post-prostatectomy radiotherapy
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On uni- and multivariate analysis, Gleason score was
the only significant predictor. The odds of PET changing
decision-making for Gleason 8–10 disease was 7.6 times
that of Gleason 6–7 disease (p = 0.01).
Discussion
This study has shown that when PSMA PET imaging is
utilised for patients seen in a radiation oncology clinic,
there can be a substantial effect on radiation oncologist
decision-making. The heterogeneous group of patients
in our cohort are consistent with what would be ex-
pected to be encountered in a radiation oncology clinic,
and strengthens the applicability of our findings to daily
practice. In our study there was a particular benefit for
patients with PSA failures post definitive or salvage
radiotherapy, and to clarify equivocal findings of conven-
tional imaging. The only other study investigating the ef-
fect of PSMA PET on decision-making was by Demirkol
[5]. This study of 22 patients being managed by urolo-
gists also found a significant impact on the management
of patients.
In our study, potentially curable patients were found
to be incurable, and potentially incurable patients were
found to be curable. Sites for radiotherapy targeting dif-
fered, doses were occasionally altered, and some patients
in the post-prostatectomy radiotherapy setting were so
reassured by a negative PSMA that they opted not to
have any therapy at all (despite recommendations to the
contrary). Equivocal findings on conventional imaging
were often found to be negative on PSMA, confirming a
treatment plan even though not altering it. This high-
lights the fact that although PSMA PET appears promis-
ing, further research is required to confirm its accuracy
and limitations.
One interesting area of potential benefit is the use of
PSMA PET in patients being considered for high dose
radiotherapy for oligometastatic disease. This is an area
of significant interest for radiation oncologists [7], and
PSMA PET appears to have the potential to identify
early oligometastatic disease as well help aid targeting of
radiotherapy, although whether this improves patient
outcomes is unknown. This is an area ripe for further
investigation.
Another area where PSMA PET may be useful is in
detecting systemic disease to allow earlier administra-
tion of systemic therapy in the clinical trial setting. Ef-
fectively PSMA PET has the potential to change
outcomes (changing disease status from PSA-only fail-
ure with conventional imaging to metastatic failure).
This change may have an adverse effect on published
metastasis-free survival outcomes after radical treat-
ments. However with earlier oligometastatic and
systemic therapy initiation, this could theoretically im-
prove prostate-cancer specific and overall survival. It is
clear that further research is required not only to evalu-
ate the diagnostic efficacy of PSMA PET, but to deter-
mine whether earlier detection and treatment of disease
(regardless of the modality of diagnostic imaging used)
translates into survival or quality-of-life benefits.
In conclusion, in our cohort PSMA PET had a signifi-
cant impact on radiation oncologist decision-making,
and impacted on patient management outcomes.
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Radical radiotherapy (to prostate or prostate
bed)
31.5 27.8
Radical radiotherapy including nodes 1.9 0
Palliative radiotherapy to oligometastases 9.3 37.0
Systemic therapy alone 7.4 16.7
Table 2 Effect of PSMA PET on disease status outcomes and
radiation oncologist decision-making
PSMA vs Conventional scans PSMA-/CS- 17 (31.5 %)
PSMA+/CS- 25 (46.3 %)
PSMA-/CS+ 7 (13.0 %)
PSMA+/CS+ 5 (9.3 %)
Change in RT management No 29 (53.7 %)
Yes 25 (46.3 %)
Change in ADT management No 36 (66.7 %)
Yes 18 (33.3 %)
Any change in management No 25 (46.3 %)
Yes 29 (53.7 %)




ADT = androgen deprivation therapy
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